[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

Global Multiple Sclerosis (MS) Drugs Market Professional Survey Report 2017

December 2017 | 112 pages | ID: GB08398AAC2EN
QYResearch

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report studies Multiple Sclerosis (MS) Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
  • Bayer AG
  • Bayhill Therapeutics
  • Biogen Idec
  • Cinnagen
  • Daiichi Sankyo
  • Eli Lilly
  • Fast Forward Llc
  • Antisense Therapeutics
  • Apitope
  • Five Prime Therapeutics
  • Genmab
  • Artielle Immunotherapeutics
  • Genzyme
  • Glaxosmithkline
  • Gw Pharmaceuticals
  • Innate Immunotherapeutics
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • Copaxone (Glatiramer Acetate, Copolymer 1)
  • Novantrone (Mitoxantrone)
  • Gilenya (Fingolimod, Fty720)
  • Aubagio (Teriflunomide)
  • Tecfidera (Dimethyl Fumarate)
  • Firategrast (Sb683699, T-0047)
  • Siponimod (Baf312)
  • Others
By Application, the market can be split into
  • RRMS
  • SPMS
  • PPMS
  • PRMS
By Regions, this report covers (we can add the regions/countries as you want)
  • North America
  • China
  • Europe
  • Southeast Asia
  • Japan
  • India
If you have any special requirements, please let us know and we will offer you the report as you want.
Global Multiple Sclerosis (MS) Drugs Market Professional Survey Report 2017

1 INDUSTRY OVERVIEW OF MULTIPLE SCLEROSIS (MS) DRUGS

1.1 Definition and Specifications of Multiple Sclerosis (MS) Drugs
  1.1.1 Definition of Multiple Sclerosis (MS) Drugs
  1.1.2 Specifications of Multiple Sclerosis (MS) Drugs
1.2 Classification of Multiple Sclerosis (MS) Drugs
  1.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
  1.2.2 Novantrone (Mitoxantrone)
  1.2.3 Gilenya (Fingolimod, Fty720)
  1.2.4 Aubagio (Teriflunomide)
  1.2.5 Tecfidera (Dimethyl Fumarate)
  1.2.6 Firategrast (Sb683699, T-0047)
  1.2.7 Siponimod (Baf312)
  1.2.8 Others
1.3 Applications of Multiple Sclerosis (MS) Drugs
  1.3.1 RRMS
  1.3.2 SPMS
  1.3.3 PPMS
  1.3.4 PRMS
1.4 Market Segment by Regions
  1.4.1 North America
  1.4.2 China
  1.4.3 Europe
  1.4.4 Southeast Asia
  1.4.5 Japan
  1.4.6 India

2 MANUFACTURING COST STRUCTURE ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs
2.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
2.4 Industry Chain Structure of Multiple Sclerosis (MS) Drugs

3 TECHNICAL DATA AND MANUFACTURING PLANTS ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

3.1 Capacity and Commercial Production Date of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
3.2 Manufacturing Plants Distribution of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
3.3 R&D Status and Technology Source of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
3.4 Raw Materials Sources Analysis of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016

4 GLOBAL MULTIPLE SCLEROSIS (MS) DRUGS OVERALL MARKET OVERVIEW

4.1 2012-2017E Overall Market Analysis
4.2 Capacity Analysis
  4.2.1 2012-2017E Global Multiple Sclerosis (MS) Drugs Capacity and Growth Rate Analysis
  4.2.2 2016 Multiple Sclerosis (MS) Drugs Capacity Analysis (Company Segment)
4.3 Sales Analysis
  4.3.1 2012-2017E Global Multiple Sclerosis (MS) Drugs Sales and Growth Rate Analysis
  4.3.2 2016 Multiple Sclerosis (MS) Drugs Sales Analysis (Company Segment)
4.4 Sales Price Analysis
  4.4.1 2012-2017E Global Multiple Sclerosis (MS) Drugs Sales Price
  4.4.2 2016 Multiple Sclerosis (MS) Drugs Sales Price Analysis (Company Segment)

5 MULTIPLE SCLEROSIS (MS) DRUGS REGIONAL MARKET ANALYSIS

5.1 North America Multiple Sclerosis (MS) Drugs Market Analysis
  5.1.1 North America Multiple Sclerosis (MS) Drugs Market Overview
  5.1.2 North America 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
  5.1.3 North America 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
  5.1.4 North America 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis
5.2 China Multiple Sclerosis (MS) Drugs Market Analysis
  5.2.1 China Multiple Sclerosis (MS) Drugs Market Overview
  5.2.2 China 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
  5.2.3 China 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
  5.2.4 China 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis
5.3 Europe Multiple Sclerosis (MS) Drugs Market Analysis
  5.3.1 Europe Multiple Sclerosis (MS) Drugs Market Overview
  5.3.2 Europe 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
  5.3.3 Europe 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
  5.3.4 Europe 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis
5.4 Southeast Asia Multiple Sclerosis (MS) Drugs Market Analysis
  5.4.1 Southeast Asia Multiple Sclerosis (MS) Drugs Market Overview
  5.4.2 Southeast Asia 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
  5.4.3 Southeast Asia 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
  5.4.4 Southeast Asia 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis
5.5 Japan Multiple Sclerosis (MS) Drugs Market Analysis
  5.5.1 Japan Multiple Sclerosis (MS) Drugs Market Overview
  5.5.2 Japan 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
  5.5.3 Japan 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
  5.5.4 Japan 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis
5.6 India Multiple Sclerosis (MS) Drugs Market Analysis
  5.6.1 India Multiple Sclerosis (MS) Drugs Market Overview
  5.6.2 India 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
  5.6.3 India 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
  5.6.4 India 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis

6 GLOBAL 2012-2017E MULTIPLE SCLEROSIS (MS) DRUGS SEGMENT MARKET ANALYSIS (BY TYPE)

6.1 Global 2012-2017E Multiple Sclerosis (MS) Drugs Sales by Type
6.2 Different Types of Multiple Sclerosis (MS) Drugs Product Interview Price Analysis
6.3 Different Types of Multiple Sclerosis (MS) Drugs Product Driving Factors Analysis
  6.3.1 Copaxone (Glatiramer Acetate, Copolymer 1) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
  6.3.2 Novantrone (Mitoxantrone) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
  6.3.3 Gilenya (Fingolimod, Fty720) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
  6.3.4 Aubagio (Teriflunomide) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
  6.3.5 Tecfidera (Dimethyl Fumarate) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
  6.3.6 Firategrast (Sb683699, T-0047) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
  6.3.7 Siponimod (Baf312) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
  6.3.8 Others of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis

7 GLOBAL 2012-2017E MULTIPLE SCLEROSIS (MS) DRUGS SEGMENT MARKET ANALYSIS (BY APPLICATION)

7.1 Global 2012-2017E Multiple Sclerosis (MS) Drugs Consumption by Application
7.2 Different Application of Multiple Sclerosis (MS) Drugs Product Interview Price Analysis
7.3 Different Application of Multiple Sclerosis (MS) Drugs Product Driving Factors Analysis
  7.3.1 RRMS of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
  7.3.2 SPMS of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
  7.3.3 PPMS of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
  7.3.4 PRMS of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis

8 MAJOR MANUFACTURERS ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

8.1 Bayer AG
  8.1.1 Company Profile
  8.1.2 Product Picture and Specifications
    8.1.2.1 Product A
    8.1.2.2 Product B
  8.1.3 Bayer AG 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.1.4 Bayer AG 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
8.2 Bayhill Therapeutics
  8.2.1 Company Profile
  8.2.2 Product Picture and Specifications
    8.2.2.1 Product A
    8.2.2.2 Product B
  8.2.3 Bayhill Therapeutics 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.2.4 Bayhill Therapeutics 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
8.3 Biogen Idec
  8.3.1 Company Profile
  8.3.2 Product Picture and Specifications
    8.3.2.1 Product A
    8.3.2.2 Product B
  8.3.3 Biogen Idec 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.3.4 Biogen Idec 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
8.4 Cinnagen
  8.4.1 Company Profile
  8.4.2 Product Picture and Specifications
    8.4.2.1 Product A
    8.4.2.2 Product B
  8.4.3 Cinnagen 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.4.4 Cinnagen 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
8.5 Daiichi Sankyo
  8.5.1 Company Profile
  8.5.2 Product Picture and Specifications
    8.5.2.1 Product A
    8.5.2.2 Product B
  8.5.3 Daiichi Sankyo 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.5.4 Daiichi Sankyo 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
8.6 Eli Lilly
  8.6.1 Company Profile
  8.6.2 Product Picture and Specifications
    8.6.2.1 Product A
    8.6.2.2 Product B
  8.6.3 Eli Lilly 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.6.4 Eli Lilly 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
8.7 Fast Forward Llc
  8.7.1 Company Profile
  8.7.2 Product Picture and Specifications
    8.7.2.1 Product A
    8.7.2.2 Product B
  8.7.3 Fast Forward Llc 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.7.4 Fast Forward Llc 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
8.8 Antisense Therapeutics
  8.8.1 Company Profile
  8.8.2 Product Picture and Specifications
    8.8.2.1 Product A
    8.8.2.2 Product B
  8.8.3 Antisense Therapeutics 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.8.4 Antisense Therapeutics 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
8.9 Apitope
  8.9.1 Company Profile
  8.9.2 Product Picture and Specifications
    8.9.2.1 Product A
    8.9.2.2 Product B
  8.9.3 Apitope 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.9.4 Apitope 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
8.10 Five Prime Therapeutics
  8.10.1 Company Profile
  8.10.2 Product Picture and Specifications
    8.10.2.1 Product A
    8.10.2.2 Product B
  8.10.3 Five Prime Therapeutics 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
  8.10.4 Five Prime Therapeutics 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
8.11 Genmab
8.12 Artielle Immunotherapeutics
8.13 Genzyme
8.14 Glaxosmithkline
8.15 Gw Pharmaceuticals
8.16 Innate Immunotherapeutics

9 DEVELOPMENT TREND OF ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS MARKET

9.1 Global Multiple Sclerosis (MS) Drugs Market Trend Analysis
  9.1.1 Global 2017-2022 Multiple Sclerosis (MS) Drugs Market Size (Volume and Value) Forecast
  9.1.2 Global 2017-2022 Multiple Sclerosis (MS) Drugs Sales Price Forecast
9.2 Multiple Sclerosis (MS) Drugs Regional Market Trend
  9.2.1 North America 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
  9.2.2 China 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
  9.2.3 Europe 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
  9.2.4 Southeast Asia 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
  9.2.5 Japan 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
  9.2.6 India 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
9.3 Multiple Sclerosis (MS) Drugs Market Trend (Product Type)
9.4 Multiple Sclerosis (MS) Drugs Market Trend (Application)

10 MULTIPLE SCLEROSIS (MS) DRUGS MARKETING TYPE ANALYSIS

10.1 Multiple Sclerosis (MS) Drugs Regional Marketing Type Analysis
10.2 Multiple Sclerosis (MS) Drugs International Trade Type Analysis
10.3 Traders or Distributors with Contact Information of Multiple Sclerosis (MS) Drugs by Region
10.4 Multiple Sclerosis (MS) Drugs Supply Chain Analysis

11 CONSUMERS ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

11.1 Consumer 1 Analysis
11.2 Consumer 2 Analysis
11.3 Consumer 3 Analysis
11.4 Consumer 4 Analysis

12 CONCLUSION OF THE GLOBAL MULTIPLE SCLEROSIS (MS) DRUGS MARKET PROFESSIONAL SURVEY REPORT 2017

Methodology
Analyst Introduction
Data Source


The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Picture of Multiple Sclerosis (MS) Drugs
Table Product Specifications of Multiple Sclerosis (MS) Drugs
Table Classification of Multiple Sclerosis (MS) Drugs
Figure Global Production Market Share of Multiple Sclerosis (MS) Drugs by Type in 2016
Figure Copaxone (Glatiramer Acetate, Copolymer 1) Picture
Table Major Manufacturers of Copaxone (Glatiramer Acetate, Copolymer 1)
Figure Novantrone (Mitoxantrone) Picture
Table Major Manufacturers of Novantrone (Mitoxantrone)
Figure Gilenya (Fingolimod, Fty720) Picture
Table Major Manufacturers of Gilenya (Fingolimod, Fty720)
Figure Aubagio (Teriflunomide) Picture
Table Major Manufacturers of Aubagio (Teriflunomide)
Figure Tecfidera (Dimethyl Fumarate) Picture
Table Major Manufacturers of Tecfidera (Dimethyl Fumarate)
Figure Firategrast (Sb683699, T-0047) Picture
Table Major Manufacturers of Firategrast (Sb683699, T-0047)
Figure Siponimod (Baf312) Picture
Table Major Manufacturers of Siponimod (Baf312)
Figure Others Picture
Table Major Manufacturers of Others
Table Applications of Multiple Sclerosis (MS) Drugs
Figure Global Consumption Volume Market Share of Multiple Sclerosis (MS) Drugs by Application in 2016
Figure RRMS Examples
Table Major Consumers in RRMS
Figure SPMS Examples
Table Major Consumers in SPMS
Figure PPMS Examples
Table Major Consumers in PPMS
Figure PRMS Examples
Table Major Consumers in PRMS
Figure Market Share of Multiple Sclerosis (MS) Drugs by Regions
Figure North America Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2012-2022)
Figure China Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2012-2022)
Figure Europe Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2012-2022)
Figure Southeast Asia Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2012-2022)
Figure Japan Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2012-2022)
Figure India Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2012-2022)
Table Multiple Sclerosis (MS) Drugs Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs in 2016
Figure Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
Figure Industry Chain Structure of Multiple Sclerosis (MS) Drugs
Table Capacity and Commercial Production Date of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
Table Manufacturing Plants Distribution of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
Table R&D Status and Technology Source of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
Table Raw Materials Sources Analysis of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
Table Global Capacity, Sales, Price, Cost, Sales Revenue (M USD) and Gross Margin of Multiple Sclerosis (MS) Drugs 2012-2017
Figure Global 2012-2017E Multiple Sclerosis (MS) Drugs Market Size (Volume) and Growth Rate
Figure Global 2012-2017E Multiple Sclerosis (MS) Drugs Market Size (Value) and Growth Rate
Table 2012-2017E Global Multiple Sclerosis (MS) Drugs Capacity and Growth Rate
Table 2016 Global Multiple Sclerosis (MS) Drugs Capacity (K Pcs) List (Company Segment)
Table 2012-2017E Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate
Table 2016 Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) List (Company Segment)
Table 2012-2017E Global Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs)
Table 2016 Global Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs) List (Company Segment)
Figure North America Capacity Overview
Table North America Supply, Import, Export and Consumption (K Pcs) of Multiple Sclerosis (MS) Drugs 2012-2017E
Figure North America 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs)
Figure North America 2016 Multiple Sclerosis (MS) Drugs Sales Market Share
Figure China Capacity Overview
Table China Supply, Import, Export and Consumption (K Pcs) of Multiple Sclerosis (MS) Drugs 2012-2017E
Figure China 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs)
Figure China 2016 Multiple Sclerosis (MS) Drugs Sales Market Share
Figure Europe Capacity Overview
Table Europe Supply, Import, Export and Consumption (K Pcs) of Multiple Sclerosis (MS) Drugs 2012-2017E
Figure Europe 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs)
Figure Europe 2016 Multiple Sclerosis (MS) Drugs Sales Market Share
Figure Southeast Asia Capacity Overview
Table Southeast Asia Supply, Import, Export and Consumption (K Pcs) of Multiple Sclerosis (MS) Drugs 2012-2017E
Figure Southeast Asia 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs)
Figure Southeast Asia 2016 Multiple Sclerosis (MS) Drugs Sales Market Share
Figure Japan Capacity Overview
Table Japan Supply, Import, Export and Consumption (K Pcs) of Multiple Sclerosis (MS) Drugs 2012-2017E
Figure Japan 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs)
Figure Japan 2016 Multiple Sclerosis (MS) Drugs Sales Market Share
Figure India Capacity Overview
Table India Supply, Import, Export and Consumption (K Pcs) of Multiple Sclerosis (MS) Drugs 2012-2017E
Figure India 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs)
Figure India 2016 Multiple Sclerosis (MS) Drugs Sales Market Share
Table Global 2012-2017E Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type
Table Different Types Multiple Sclerosis (MS) Drugs Product Interview Price
Table Global 2012-2017E Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application
Table Different Application Multiple Sclerosis (MS) Drugs Product Interview Price
Table Bayer AG Information List
Table Product A Overview
Table Product B Overview
Table 2016 Bayer AG Multiple Sclerosis (MS) Drugs Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure 2016 Bayer AG Multiple Sclerosis (MS) Drugs Business Region Distribution
Table Bayhill Therapeutics Information List
Table Product A Overview
Table Product B Overview
Table 2016 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure 2016 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Business Region Distribution
Table Biogen Idec Information List
Table Product A Overview
Table Product B Overview
Table 2015 Biogen Idec Multiple Sclerosis (MS) Drugs Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure 2016 Biogen Idec Multiple Sclerosis (MS) Drugs Business Region Distribution
Table Cinnagen Information List
Table Product A Overview
Table Product B Overview
Table 2016 Cinnagen Multiple Sclerosis (MS) Drugs Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure 2016 Cinnagen Multiple Sclerosis (MS) Drugs Business Region Distribution
Table Daiichi Sankyo Information List
Table Product A Overview
Table Product B Overview
Table 2016 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure 2016 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Business Region Distribution
Table Eli Lilly Information List
Table Product A Overview
Table Product B Overview
Table 2016 Eli Lilly Multiple Sclerosis (MS) Drugs Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure 2016 Eli Lilly Multiple Sclerosis (MS) Drugs Business Region Distribution
Table Fast Forward Llc Information List
Table Product A Overview
Table Product B Overview
Table 2016 Fast Forward Llc Multiple Sclerosis (MS) Drugs Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure 2016 Fast Forward Llc Multiple Sclerosis (MS) Drugs Business Region Distribution
Table Antisense Therapeutics Information List
Table Product A Overview
Table Product B Overview
Table 2016 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure 2016 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Business Region Distribution
Table Apitope Information List
Table Product A Overview
Table Product B Overview
Table 2016 Apitope Multiple Sclerosis (MS) Drugs Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure 2016 Apitope Multiple Sclerosis (MS) Drugs Business Region Distribution
Table Five Prime Therapeutics Information List
Table Product A Overview
Table Product B Overview
Table 2016 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure 2016 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Business Region Distribution
Table Genmab Information List
Table Artielle Immunotherapeutics Information List
Table Genzyme Information List
Table Glaxosmithkline Information List
Table Gw Pharmaceuticals Information List
Table Innate Immunotherapeutics Information List
Figure Global 2017-2022 Multiple Sclerosis (MS) Drugs Market Size (K Pcs) and Growth Rate Forecast
Figure Global 2017-2022 Multiple Sclerosis (MS) Drugs Market Size (Million USD) and Growth Rate Forecast
Figure Global 2017-2022 Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs) Forecast
Figure North America 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Volume (K Pcs) and Growth Rate Forecast
Figure China 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Europe 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Southeast Asia 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Japan 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Volume (K Pcs) and Growth Rate Forecast
Figure India 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Volume (K Pcs) and Growth Rate Forecast
Table Global Sales Volume (K Pcs) of Multiple Sclerosis (MS) Drugs by Type 2017-2022
Table Global Consumption Volume (K Pcs) of Multiple Sclerosis (MS) Drugs by Application 2017-2022
Table Traders or Distributors with Contact Information of Multiple Sclerosis (MS) Drugs by Region

More Publications

Need Help?

Ask a Question

Market Reports

All Categories